Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Xolair in Moderate to Severe Persistent Asthma (ALTO)
NCT00401596Phase 3Completed
- Sponsor
- Genentech
- Start
- Jul 2000
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of omalizumab in asthma, sponsored by Genentech. Started Jul 2000; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00401596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00401596.